These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments.   

investors@repligen.com

SEC Filings

Other Filings
Filing Description Filing Type Filing Date Event Date  
8-K 8-K/A 6/26/2017 6/22/2017
Abstract: Registrant filed an amendment to the Form 8-K filed June 23 to provide the historical financial statements of Spectrum Inc. under Item 9.01(a) and the pro forma financial information required under Item 9.01(b).
Prospectus 424B5 6/26/2017
8-K 8-K 6/23/2017 6/22/2017
Abstract: 8-K filed by Repligen Corp. (RGEN) covering Entry into a Material Definitive Agreement; Regulation FD Disclosure; and Financial Statements and Exhibits.
8-K 8-K 5/23/2017 5/18/2017
Abstract: 8-K filed by Repligen Corp. (RGEN) covering Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holder; and Financial Statements and Exhibits.
8-K 8-K 5/4/2017 5/4/2017
Abstract: 8-K filed by Repligen Corp. (RGEN) covering Results of Operations and Financial Condition and Financial Statements and Exhibits.
10-Q 10-Q 5/4/2017 3/31/2017
Proxy DEF 14A 4/21/2017 5/18/2017
Proxy PRE 14A 4/7/2017 5/18/2017
8-K 8-K/A 3/1/2017 12/14/2016
Abstract: 8-K filed by Repligen Corp. (RGEN) covering Completion of Acquisition or Disposition of Assets and Financial Statements and Exhibits.
10-K 10-K 2/23/2017 12/31/2016
8-K 8-K 2/22/2017 2/22/2017
Abstract: 8-K filed by Repligen Corp. (RGEN) covering Results of Operations and Financial Condition and Financial Statements and Exhibits.
13-D SC 13G/A 2/14/2017
13-D SC 13G/A 2/6/2017
13-D SC 13G/A 2/1/2017
13-D SC 13G/A 1/17/2017
Annual Report AR 12/31/2016
8-K 8-K 12/15/2016 12/14/2016
Abstract: On Dec. 15, registrant announced that it acquired TangenX Technology Corp. of Shrewsbury, maker of the innovative single use sius line of tangential flow filtration cassettes and hardware used in downstream biopharmaceutical manufacturing processes. The stock purchase agreement was included by exhibit.
8-K 8-K 11/3/2016 11/3/2016
Abstract: On Nov. 3, registrant reported its net income for the quarter ended Sept. 30.
10-Q 10-Q 11/3/2016 9/30/2016
8-K 8-K 9/2/2016 8/31/2016
Abstract: 8-K filed by Repligen (RGEN) covering Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers and Financial Statements and Exhibits.

Displaying 1 to 20 (of 117 filings)